S Suissa, B Hemmelgarn, L Blais and P Ernst
McGill Pharmacoepidemiology Research Unit, Department of Medicine, Royal Victoria Hospital, Montreal, Quebec, Canada.

Bronchodilators used in the treatment of airway disease have been shown to have a variety of cardiac effects that may contribute to the occurrence of life-threatening events such as cardiac arrhythmias and cardiac arrest. We investigated whether theophylline and beta-agonists were associated with cardiovascular mortality among a cohort of subjects prescribed antiasthma medications. We used a population-based cohort of 12,301 subjects aged 5 to 54 yr, formed from health-insurance data bases from Saskatchewan, Canada, and spanning the period 1978 to 1987. Within this cohort, we identified all 30 deaths from cardiovascular causes in which acute asthma did not appear to be a contributing factor. We identified all asthma and cardiovascular drugs dispensed to these subjects shortly before their deaths and compared this therapy to that dispensed to a random sample of 4,080 person-time controls. After adjustment for age and the prior use of cardiac drugs, the rate of cardiovascular death was greater in users of theophylline, with a rate ratio (RR) of 2.7 (95% Cl:1.2 to 6.1), and in users of beta- agonists taken orally or by nebulizer (RR = 2.4; 95% Cl:1.0 to 5.4), but not in users of beta-agonists administered by metered-dose inhaler (RR = 1.2; 95% Cl:0.5 to 2.7). The great majority of cardiovascular deaths occurred among subjects with clinical or pathologic evidence of potentially lethal conditions. These results suggest that the use of theophylline and of beta-agonists administered orally or by nebulization should be avoided in subjects with significant cardiac disease or at high risk for such disease, especially acute coronary insufficiency and congestive cardiomyopathy. On the other hand, the use of beta-agonists administered by metered-dose inhalers (MDIs) was not associated with an increased risk of cardiovascular death.

This article has been cited by other articles:

				M T Dransfield, S M Rowe, J E Johnson, W C Bailey, and L B Gerald Use of {beta} blockers and the risk of death in hospitalised patients with acute exacerbations of COPD Thorax, April 1, 2008; 63(4): 301 - 305. [Abstract] [Full Text] [PDF]

				T.-M. Lee, M.-S. Lin, and N.-C. Chang Inhibition of histone deacetylase on ventricular remodeling in infarcted rats Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H968 - H977. [Abstract] [Full Text] [PDF]

				D. J. Eckert, A. S. Jordan, P. Merchia, and A. Malhotra Central Sleep Apnea: Pathophysiology and Treatment Chest, February 1, 2007; 131(2): 595 - 607. [Abstract] [Full Text] [PDF]

				H. Schubiner, B. Hassunizadeh, and R. Kaczynski A controlled study of autonomic nervous system function in adults with attention-deficit/hyperactivity disorder treated with stimulant medications: results of a pilot study. J Atten Disord, November 1, 2006; 10(2): 205 - 211. [Abstract] [PDF]

				B. M. RuDusky Acute myocardial infarction and status asthmaticus: a case report. Angiology, October 1, 2006; 57(5): 655 - 658. [Abstract] [PDF]

				A Bruton and M Thomas Breathing therapies and bronchodilator use in asthma. Thorax, August 1, 2006; 61(8): 643 - 645. [Full Text] [PDF]

				M. Arzt and T. D. Bradley Treatment of Sleep Apnea in Heart Failure Am. J. Respir. Crit. Care Med., June 15, 2006; 173(12): 1300 - 1308. [Abstract] [Full Text] [PDF]

				L. Huiart, P. Ernst, and S. Suissa Cardiovascular Morbidity and Mortality in COPD Chest, October 1, 2005; 128(4): 2640 - 2646. [Abstract] [Full Text] [PDF]

				E. M. Kallergis, E. G. Manios, E. M. Kanoupakis, S. E. Schiza, H. E. Mavrakis, N. K. Klapsinos, and P. E. Vardas Acute Electrophysiologic Effects of Inhaled Salbutamol in Humans Chest, June 1, 2005; 127(6): 2057 - 2063. [Abstract] [Full Text] [PDF]

				H R. Anderson, J. G Ayres, P. M Sturdy, J M. Bland, B. K Butland, C. Peckitt, J. C Taylor, C. R Victor, and for the Mortality and Severe Morbidity Group of th Bronchodilator treatment and deaths from asthma: case-control study BMJ, January 15, 2005; 330(7483): 117. [Abstract] [Full Text] [PDF]

				S. Andreas, H. Reiter, L. Luthje, A. Delekat, R. W. Grunewald, G. Hasenfuss, and V. K. Somers Differential Effects of Theophylline on Sympathetic Excitation, Hemodynamics, and Breathing in Congestive Heart Failure Circulation, October 12, 2004; 110(15): 2157 - 2162. [Abstract] [Full Text] [PDF]

				S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter Cardiovascular Effects of {beta}-Agonists in Patients With Asthma and COPD: A Meta-Analysis Chest, June 1, 2004; 125(6): 2309 - 2321. [Abstract] [Full Text] [PDF]

				R Reading, T Jones, and C Upton Emergency asthma inhalers in school Arch. Dis. Child., May 1, 2003; 88(5): 384 - 386. [Abstract] [Full Text] [PDF]

				S Suissa, T Assimes, and P Ernst Inhaled short acting {beta} agonist use in COPD and the risk of acute myocardial infarction Thorax, January 1, 2003; 58(1): 43 - 46. [Abstract] [Full Text] [PDF]

				D. H. Au, J. R. Curtis, N. R. Every, M. B. McDonell, and S. D. Fihn Association Between Inhaled {beta}-Agonists and the Risk of Unstable Angina and Myocardial Infarction Chest, March 1, 2002; 121(3): 846 - 851. [Abstract] [Full Text] [PDF]

				H. W. Kelly The Management of Acute Severe Asthma Journal of Pharmacy Practice, April 1, 2001; 14(2): 91 - 107. [Abstract] [PDF]

				D. H. AU, R. N. LEMAITRE, J. RANDALL CURTIS, N. L. SMITH, and B. M. PSATY The Risk of Myocardial Infarction Associated with Inhaled beta -Adrenoceptor Agonists Am. J. Respir. Crit. Care Med., March 1, 2000; 161(3): 827 - 830. [Abstract] [Full Text] [PDF]

				H. F Guite, R. Dundas, and P. G J Burney Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma Thorax, April 1, 1999; 54(4): 301 - 307. [Abstract] [Full Text]

				P. Chervinsky, P. Goldberg, S. Galant, Y. Wang, T. Arledge, M. B. Welch, and E. Stahl Long-term Cardiovascular Safety of Salmeterol Powder Pharmacotherapy in Adolescent and Adult Patients With Chronic Persistent Asthma: A Randomized Clinical Trial Chest, March 1, 1999; 115(3): 642 - 648. [Abstract] [Full Text] [PDF]

				R. M Martin, N. R Dunn, S. N Freemantle, and R. D Mann Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists Thorax, July 1, 1998; 53(7): 558 - 562. [Abstract] [Full Text]